New Therapies for the Treatment of Inflammatory Bowel Disease

Surgical Clinics of North America

Volumn 86, Issue 4, 2006, Pages 1045-1064

  Sands, Bruce E ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ABT 874; ADALIMUMAB; ALICAFORSEN; AZATHIOPRINE; BASILIXIMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DACLIZUMAB; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; ETANERCEPT; FONTOLIZUMAB; GAMMA INTERFERON ANTIBODY; HYDROCORTISONE; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; MERCAPTOPURINE; METHOTREXATE; MLN 02; NATALIZUMAB; ONERCEPT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH HORMONE; SEMAPIMOD; STEROID; TETOMILAST; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ARTHRALGIA; AUTOIMMUNE DISEASE; BACKACHE; BIRTH DEFECT; BONE PAIN; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; COST BENEFIT ANALYSIS; CROHN DISEASE; CYTAPHERESIS; DELAYED HYPERSENSITIVITY; DERMATITIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENTERITIS; FEVER; HELMINTHIASIS; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LEUKOPENIA; LIVER TOXICITY; LUPUS LIKE SYNDROME; LYMPHOMA; META ANALYSIS; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PHLEBITIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TUBERCULOSIS; ULCERATIVE COLITIS;

CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 33746894599     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2006.05.009     Document Type: Review

References (68)

1. Braegger C.P., Nicholls S., Murch S.H., et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. [see comment]. Lancet 339 8785 (1992) 89-91
2. Reinecker H.C., Steffen M., Witthoeft T., et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients who have ulcerative colitis and Crohn's disease. Clin Exp Immunol 94 1 (1993) 174-181
3. van Dullemen H.M., van Deventer S.J., Hommes D.W., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 1 (1995) 129-135
4. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 15 (1997) 1029-1035
5. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 18 (1999) 1398-1405
6. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. [see comment]. Lancet 359 9317 (2002) 1541-1549
7. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. [see comment]. N Engl J Med 350 9 (2004) 876-885
8. Sands B.E., Blank M.A., Patel K., et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2 10 (2004) 912-920
9. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 1 (2004) 19-31
10. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. [see comment]. Gastroenterology 126 2 (2004) 402-413
11. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. [see comment]. N Engl J Med 348 7 (2003) 601-608
12. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. [see comment]. Gastroenterology 124 4 (2003) 917-924
13. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128 4 (2005) 862-869
14. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. [see comment]. N Engl J Med 345 15 (2001) 1098-1104
15. Sands B.E., Tremaine W.J., Sandborn W.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. [see comment]. Inflamm Bowel Dis 7 2 (2001) 83-88
16. Probert C.S., Hearing S.D., Schreiber S., et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52 7 (2003) 998-1002
17. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (2005) 2462-2476
18. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. [see comment]. Gastroenterology 128 7 (2005) 1805-1811
19. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. [see comment]. N Engl J Med 330 26 (1994) 1841-1845
20. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120 6 (2001) 1330-1338
21. Sandborn W.J., Feagan B.G., Radford-Smith G., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53 10 (2004) 1485-1493
22. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. [see comment]. Gastroenterology 121 5 (2001) 1088-1094
23. Rutgeerts P., Lemmens L., Van Assche G., et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 17 2 (2003) 185-192
24. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. [see comment]. Gastroenterology 129 3 (2005) 807-818
25. Hanauer S., Sandborn W.J., Rutgeerts P.J., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial. Gastroenterology 130 2 (2006) 323-333
26. Sandborn W.J., Hanauer S., Lukas M., et al. Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study. Gut 54 Suppl VII (2005) A81
27. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Certolizumab pegol, a humanized anti-TNF pegylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECISE). Gut 54 Suppl VII (2005) A82
28. Travis S., Yap L.M., Hawkey C., et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 11 8 (2005) 713-719
29. Ehrenpreis E.D., Kane S.V., Cohen L.B., et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. [see comment]. Gastroenterology 117 6 (1999) 1271-1277
30. Vasiliauskas E.A., Kam L.Y., Abreu-Martin M.T., et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. [see comment]. Gastroenterology 117 6 (1999) 1278-1287
31. Hommes D., van den Blink B., Plasse T., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. [see comment]. Gastroenterology 122 1 (2002) 7-14
32. Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 39 7 (2005) 557-569 [erratum: J Clin Gastroenterol 2005;39(9):843]
33. Hanauer S.B., Miner P.B., Keshavarzian A., et al. Randomized, double-blind, placebo-controlled, parallel arm, safety and efficacy trial of once-daily, oral OPC-6535 in the treatment of active ulcerative colitis (UC). Gastroenterology 126 4, Suppl 2 (2004) A112-A113
34. Mannon P.J., Fuss I.J., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. [see comment]. N Engl J Med 351 20 (2004) 2069-2079 [erratum: N Engl J Med 2005;352(12):1276]
35. Hommes D., Mikhajlova T., Stoinov S., et al. Fontolizumab (HuZaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gastroenterology 127 1 (2004) 332
36. Kotsev I., de Villiers W.J.S., Katz S., et al. Fontolizumab (HuZAF), a humanized anti-IFN-gamma antibody, in patients with moderate to severe Crohn's disease (CD), is active and well tolerated in a multi-dose study. Gut 54 Suppl VII (2005) A19
37. Ito H., Takazoe M., Fukuda Y., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 4 (2004) 989-996 [discussion: 947]
38. Sands B.E. Therapy of inflammatory bowel disease. Gastroenterology 118 Suppl 1 (2000) S68-S82
39. Jacobsohn D.A., and Vogelsang G.B. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des 10 11 (2004) 1195-1205
40. Van Assche G., Dalle I., Noman M., et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 98 2 (2003) 369-376
41. Creed T.J., Norman M.R., Probert C.S., et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18 1 (2003) 65-75
42. Panaccione R., Ferraz J.G., and Beck P. Advances in medical therapy of inflammatory bowel disease. Curr Opin Pharmacol 5 6 (2005) 566-572
43. Ghosh S., Goldin E., Gordon F.H., et al. Natalizumab for active Crohn's disease. [see comment]. N Engl J Med 348 1 (2003) 24-32
44. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. [see comment]. N Engl J Med 353 18 (2005) 1912-1925
45. Berger J.R., and Koralnik I.J. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. [comment]. N Engl J Med 353 4 (2005) 414-416
46. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. [see comment]. N Engl J Med 353 4 (2005) 362-368
47. Feagan B.G., Greenberg G.R., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. [see comment]. N Engl J Med 352 24 (2005) 2499-2507
48. Yacyshyn B.R., Bowen-Yacyshyn M.B., Jewell L., et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114 6 (1998) 1133-1142 [erratum: Gastroenterology 2001;121(3):747]
49. Yacyshyn B.R., Chey W.Y., Goff J., et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51 1 (2002) 30-36
50. Yacyshyn B.R., Barish C., Goff J., et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 16 10 (2002) 1761-1770
51. Miner P., Wedel M., Bane B., et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 19 3 (2004) 281-286
52. van Deventer S.J., Volfova M., Flisiak R., et al. A phase 2 dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Gastroenterolgy 128 Suppl 2 (2005) A74
53. Sands B.E., Winston B.D., Salzberg B., et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16 3 (2002) 399-406
54. Slonim A.E., Bulone L., Damore M.B., et al. A preliminary study of growth hormone therapy for Crohn's disease. [see comment]. N Engl J Med 342 22 (2000) 1633-1637
55. Sinha A., Nightingale J., West K.P., et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. [see comment]. N Engl J Med 349 4 (2003) 350-357
56. Sandborn W.J., Sands B.E., Wolf D.C., et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 17 11 (2003) 1355-1364
57. Korzenik J.R., and Dieckgraefe B.K. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci 45 6 (2000) 1121-1129
58. Dieckgraefe B.K., Korzenik J.R., Husain A., et al. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 161 Suppl 1 (2002) S88-S92
59. Korzenik J.R., and Dieckgraefe B.K. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 21 4 (2005) 391-400
60. Dieckgraefe B.K., and Korzenik J.R. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. [see comment]. Lancet 360 9344 (2002) 1478-1480
61. Korzenik J.R., Dieckgraefe B.K., Valentine J.F., et al. Sargramostim in Crohn's Disease Study G. Sargramostim for active Crohn's disease. N Engl J Med 352 21 (2005) 2193-2201
62. Summers R.W., Elliott D.E., Urban Jr. J.F., et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. [see comment]. Gastroenterology 128 4 (2005) 825-832
63. Summers R.W., Elliott D.E., Urban Jr. J.F., et al. Trichuris suis therapy in Crohn's disease. [see comment]. Gut 54 1 (2005) 87-90
64. Summers R.W., Elliott D.E., Qadir K., et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. [see comment]. Am J Gastroenterol 98 9 (2003) 2034-2041
65. Elliott D.E., Summers R.W., and Weinstock J.V. Helminths and the modulation of mucosal inflammation. Curr Opin Gastroenterol 21 (2005) 51-58
66. Sawada K., Kusugami K., Suzuki Y., et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 100 6 (2005) 1362-1369
67. Hanai H., Watanabe F., Yamada M., et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 70 1 (2004) 36-44
68. Kawamura A., Saitoh M., Yonekawa M., et al. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease. Ther Apher 3 4 (1999) 334-337